TheEdgeResearch
Home / Stocks / INDV

Indivior Pharmaceuticals Inc (INDV)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$35.82 ▼ -0.50%
Market Cap
$4.47B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.11
52-Wk Range
22.56-42.81
CEO
Joseph J. Ciaffoni
Country
US
Currency
USD

Indivior Pharmaceuticals Inc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in North Chesterfield, VA, US. The stock last traded at $35.82, down 0.50% on the session, giving a market capitalisation of $4.47B. On trailing twelve-month figures it carries a trailing P/E of 12.61, a net margin of 26.7%. Its beta of 1.11 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
12.61
Price / Sales
3.36
Price / Book
-21.59
EV / EBITDA
11.01
Gross margin
83.9%
Operating margin
38.9%
Net margin
26.7%
Return on equity
—
Debt / equity
-2.45
Current ratio
0.84
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
833
IPO date
2014-12-29
Headquarters
North Chesterfield, VA, US
About Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Comparable companies

Indivior Pharmaceuticals Inc is most often compared with the following Healthcare names:

ACADADMAAMRXCRNXHNGELNTHOPCHPRAXSUPNVKTX
More research on INDV
INDV technical analysis INDV TheEdge Score Compare against peers
Open full interactive analysis & DCF →